Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Differentiation of Common Myeloid Progenitor Cells01:15

Differentiation of Common Myeloid Progenitor Cells

Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Common Biomarkers of Endothelial Dysfunction Across Highly Prevalent Diseases with Cardiovascular Risk: Functional Characterization and Prognostic Implications.

International journal of molecular sciences·2026
Same author

Genomic profiling for decision-making in post-polycythemia vera and post-essential thrombocythemia myelofibrosis.

Blood·2026
Same author

Red blood cell immunization as an independent predictor of survival in the myelodysplastic syndromes.

British journal of haematology·2026
Same author

Prediction model for renal outcomes in Latin American Mestizo patients with pure proliferative lupus nephritis.

Lupus science & medicine·2025
Same author

Genome-wide analysis defines genetic determinants of MPN subtypes and identifies a sex-specific association at CDH22/CD40.

Blood·2025
Same author

2025 European LeukemiaNet recommendations for the management of chronic myeloid leukemia.

Leukemia·2025
Same journal

BRAF Alterations in Chronic Lymphocytic Leukemia: Genomic Landscape, Co-Mutation Patterns, and Clinical Relevance.

Current hematologic malignancy reports·2026
Same journal

Targeting the BCR::ABL1 Kinase: Advances Beyond Imatinib in Chronic Myeloid Leukemia.

Current hematologic malignancy reports·2026
Same journal

Germline DDX41 Variants: Current Understanding and Future Directions.

Current hematologic malignancy reports·2026
Same journal

Clonal Signatures of Telomere Biology Disorders.

Current hematologic malignancy reports·2026
Same journal

Molecular Pathogenesis and Targeted Therapies for Myeloproliferative Hypereosinophilic Neoplasms.

Current hematologic malignancy reports·2026
Same journal

The Intricate Dance Between Inflammation and Myeloproliferative Neoplasms: From Origins to Outcomes.

Current hematologic malignancy reports·2026
See all related articles

Related Experiment Video

Updated: May 27, 2026

Interphase Fluorescence in situ Hybridization of Bone Marrow Smears of Multiple Myeloma
07:53

Interphase Fluorescence in situ Hybridization of Bone Marrow Smears of Multiple Myeloma

Published on: April 15, 2022

Prognostication in primary myelofibrosis.

Francisco Cervantes1, Arturo Pereira

  • 1Hematology Department, Hospital Clínic, IDIBAPS, University of Barcelona, Villarroel 170, Barcelona, Spain. fcervan@clinic.ub.es

Current Hematologic Malignancy Reports
|November 11, 2011
PubMed
Summary
This summary is machine-generated.

Primary myelofibrosis (PMF) is a rare blood cancer. Prognostic models like DIPSS and DIPSS-plus help predict patient outcomes and guide treatment decisions for this Philadelphia chromosome-negative neoplasm.

More Related Videos

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
09:01

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

Published on: March 26, 2018

Database-guided Flow-cytometry for Evaluation of Bone Marrow Myeloid Cell Maturation
12:05

Database-guided Flow-cytometry for Evaluation of Bone Marrow Myeloid Cell Maturation

Published on: November 3, 2018

Related Experiment Videos

Last Updated: May 27, 2026

Interphase Fluorescence in situ Hybridization of Bone Marrow Smears of Multiple Myeloma
07:53

Interphase Fluorescence in situ Hybridization of Bone Marrow Smears of Multiple Myeloma

Published on: April 15, 2022

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
09:01

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

Published on: March 26, 2018

Database-guided Flow-cytometry for Evaluation of Bone Marrow Myeloid Cell Maturation
12:05

Database-guided Flow-cytometry for Evaluation of Bone Marrow Myeloid Cell Maturation

Published on: November 3, 2018

Area of Science:

  • Hematology
  • Oncology
  • Genetics

Background:

  • Primary myelofibrosis (PMF) is a Philadelphia chromosome-negative chronic myeloproliferative neoplasm.
  • It primarily affects elderly individuals, with a median survival of approximately 6 years.
  • PMF can progress to acute leukemia in 10-20% of cases, and current treatments are largely palliative.

Purpose of the Study:

  • To review the prognostic factors and scoring systems for primary myelofibrosis.
  • To highlight the importance of accurate prognostication for treatment decisions, including allogeneic hemopoietic stem-cell transplantation (allo-HSCT).
  • To discuss the evolution of prognostic models from IPSS to DIPSS and DIPSS-plus.

Main Methods:

  • Review of existing literature on primary myelofibrosis prognostication.
  • Analysis of key prognostic factors including age, anemia, constitutional symptoms, leukocytosis, blood blasts, and cytogenetic abnormalities.
  • Description of the development and refinement of prognostic scoring systems (IPSS, DIPSS, DIPSS-plus).

Main Results:

  • Key prognostic factors for PMF include anemia, age >65 years, constitutional symptoms, leukocytosis, blood blasts, and cytogenetic abnormalities.
  • The International Prognostic Scoring System (IPSS) and its dynamic version (DIPSS) provide a framework for risk stratification.
  • The DIPSS-plus model incorporates karyotypic information for enhanced prognostic accuracy.

Conclusions:

  • Accurate prognostication is crucial in managing primary myelofibrosis, especially with advancements in allo-HSCT and targeted therapies.
  • IPSS, DIPSS, and DIPSS-plus are valuable tools for assessing patient risk and guiding clinical management.
  • Further research into molecular-targeted therapies and less aggressive transplantation methods is warranted.